Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy

Bibliographic Details
Main Authors:	Vandercam Bernard, Goubau Patrick, Yombi Jean-Cyr, Kabamba Benoît, Fairon Yvette, Henrivaux Philippe
Format:	Article
Language:	English
Published:	BMC 2010-05-01
Series:	Retrovirology

Similar Items

Lopinavir- und Efavirenz-Serumkonzentrationen bei antiretroviral behandelten HIV-infizierten Kindern in Südafrika
by: von Bibra, Mirjam
Published: (2019)

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
by: Jan Vesterbacka, et al.
Published: (2013-01-01)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
by: Nilkamhang Samruay, et al.
Published: (2009-12-01)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
by: Manosuthi Weerawat, et al.
Published: (2012-03-01)

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
by: Cicconi Paola, et al.
Published: (2011-01-01)

Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
by: Bin Su, et al.
Published: (2019-12-01)

Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler<sup>® </sup>Real-time PCR
by: Bodéus Monique, et al.
Published: (2005-03-01)

Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens
by: A. Gonzalez-Serna, et al.
Published: (2017-12-01)

Virologic outcomes of HIV-infected children undergoing a single-class drug substitution from Lopinavir/Ritonavir- to Efavirenz-based antiretroviral treatment: A retrospective cohort study
by: Reichmuth, Kirsten Leah
Published: (2015)

Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
by: Innocent Lule Segamwenge, et al.
Published: (2018-01-01)

HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting
by: Elisabetta Garagiola, et al.
Published: (2020-12-01)

Guidelines for the prevention, diagnosis and management of NRTI-hyperlactataemia and lactic acidosis
by: Editorial Office
Published: (2006-05-01)

Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia.
by: Setha Limsreng, et al.
Published: (2016-01-01)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
by: Gary Maartens
Published: (2020-01-01)

The Potential Role of Antiretroviral Efavirenz in HIV Associated Neurocognitive Disorders
by: Brown, Lecia Ashanna Moya
Published: (2017)

Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria
by: Sikiru Olatunji Usman, et al.
Published: (2020-11-01)

Vergleichende Beobachtung zweier NRTI-haltiger Kollektive mit einem NRTI-freien Kollektiv in der HIV-Primärtherapie unter kontinuierlichem Therapeutischen Drug Monitoring über 96 Wochen
by: Drechsel, F. Philipp
Published: (2010)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
by: Larru B, et al.
Published: (2014-05-01)

ANTIRETROVIRAL DRUGS EFAVIRENZ AND TENOFOVIR AND THEIR EFFECTS ON ARTERIAL REMODELING AND PROTEASE ACTIVITY
by: Roberts, Ladeidra Monet
Published: (2015)

Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
by: Rudolph L Gleason, et al.
Published: (2015-01-01)

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
by: Globahan Ajibola, et al.
Published: (2020-01-01)

Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy
by: Sheree Schwartz, et al.
Published: (2012-01-01)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
by: Selemani Saidi Sungi, et al.
Published: (2018-10-01)

Low reduction of HCV-RNA level at week 4 in HIV-1 infected patients with acute HCV Infection
by: Vincent A, et al.
Published: (2012-05-01)

Beyond the polymerase-γ theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity.
by: Reuben L Smith, et al.
Published: (2017-01-01)

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
by: Tina S Skinner-Adams, et al.
Published: (2012-01-01)

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
by: Nguyen Thi Ngoc Lan, et al.
Published: (2014-01-01)

Drug Monitoring von Lopinavir, Efavirenz und Nevirapin im Rahmen der antiretroviralen Kombinationstherapie bei Kindern und Jugendlichen mit HIV-Infektion in Kapstadt, Südafrika
by: Bauer, Nikolaus Johannes
Published: (2020)

The pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir
by: Decloedt, Eric Hermann
Published: (2015)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
by: Patience Nyakato, et al.
Published: (2020-01-01)

Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador
by: Alejandro Checa, et al.
Published: (2020-07-01)

Cardiovascular side effects of the antiretroviral agents rilpivirine, efavirenz, etravirine and abacavir : possible underlying mechanisms
by: Bergin, Hild
Published: (2014)

Untersuchungen zum Therapeutischen Drug Monitoring von Nevirapin, Efavirenz und Lopinavir im Rahmen der antiretroviralen Kombinationstherapie bei Patienten mit HIV-Infektion in Mwanza/Tansania
by: Oberhagemann, Annika
Published: (2014)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

Lopinavir/ritonavir-based second line antiretroviral treatment in children at National Pediatric Hospital, Phnom Penh, Cambodia
by: Ngin Sopheak, et al.
Published: (2009-07-01)

Nevirapine-associated liver toxicity and hypersensitivity reactions in a cohort of HIV-1-infected patients,clinical analysis
by: Jonckheere Sylvie, et al.
Published: (2012-05-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
by: Tarcyla Andrade Gomes, et al.
Published: (2015-04-01)

Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
by: Joel A Dave, et al.
Published: (2015-01-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
by: Tarcyla Andrade Gomes, et al.
Published: (2015-10-01)